Journal of Traditional Chinese Medicine >
Protective efficacy of Shenge San (参蛤散) on mitochondria in H9c2 cardiomyocytes
Received date: 2021-07-02
Accepted date: 2021-10-26
Online published: 2022-11-01
OBJECTIVE: To investigate whether peroxisome proliferator-activated receptor γ-coactivator-1α/nuclear respiratory factor 1 (PGC-1α/NRF1) activity can protect mitochondrial function in the setting of cardiac hypertrophy and improve cardiomyocyte energy metabolism.
METHODS: Cardiac hypertrophy was modeled in H9c2 cells treated with isoproterenol (ISO) to assess the effects of Shenge San (参蛤散, SGS) on cell viability and mitochondrial membrane potential. We assessed mitochondrial complex mRNA levels and mitochondrial oxidative phosphorylation factor mRNA and protein levels.
RESULTS: Compared with the 100 μM ISO group, cell size was significantly decreased in the 0.3 mg/mL SGS and 20 μM ZLN005 (PGC-1α activator) groups (P < 0.01). Compared with the SGS (0.3) +ISO group, we observed lower phosphorylated adenosine monophosphate-activated kinase (AMPK) protein levels in the ISO and ZLN005+SGS+ISO groups (P < 0.01). Compared with the compound C group, SGS significantly increased PGC-1α expression in ISO-induced cardiac hypertrophy cells (P < 0.01), and this was inhibited by compound C pretreatment (P < 0.05). Compared with the ISO group, the mitochondrial red-green fluorescence ratio increased in the 0.3 mg/mL SGS group (P < 0.05). mRNA levels of cytochrome c oxidase subunit 1 (CO1) in the ISO and compound C groups were lower than those in control group (P < 0.01), and the mRNA levels of CO1 and ATP8 were significantly lower in the ISO and compound C groups versus control (P < 0.01). Compared with the SGS (0.3) +ISO group, ATP synthetase subunit 8 (ATP8) mRNA was significantly decreased in the ISO group (P < 0.01) and compound C+SGS+ISO group (P < 0.05). Compared with the SGS (0.3) +ISO group, NRF1 mRNA levels were significantly decreased (P < 0.05) in the ISO and compound C+SGS+ISO groups.
CONCLUSIONS: SGS can attenuate ISO-induced cardiomyocyte hypertrophy, restore the decrease in mitochondrial membrane potential, and upregulate PGC-1α/NRF1 levels. Notably, these effects can be blocked by AMPK inhibitor-compound C.
Lingyan ZHU , Yihong WEI , Youhua WANG , Jianmei YANG , Jiawei LI , Min CAO , Duan ZHOU . Protective efficacy of Shenge San (参蛤散) on mitochondria in H9c2 cardiomyocytes[J]. Journal of Traditional Chinese Medicine, 2022 , 42(6) : 892 -899 . DOI: 10.19852/j.cnki.jtcm.2022.06.005
| [1] | Gogiraju R, Bochenek ML, Schäfer K. Angiogenic endothelial cell signaling in cardiac hypertrophy and heart failure. Front Cardiovasc Med 2019; 6: 20. |
| [2] | Sun K, Wang KQ, GE JB, et al. Mitochondria are important targets for the prevention and treatment of heart failure. Zhong Guo Xin Xue Guan Bing Za Zhi 2008; 36: 854-9. |
| [3] | Qiu ZL, Wei Y, Song QQ, et al. The role of myocardial mitochondrial quality control in heart failure. Front Pharmacol 2019; 10: 1404. |
| [4] | Sebastiani M, Giordano C, Nediani C, et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol 2007; 50: 1362-9. |
| [5] | Joseph AH, Eric NO. Cardiac plasticity. N Engl J Med 2008; 358: 1370-80. |
| [6] | Zhao J. Sheng Ji Zong Lu. Beijing: People's Medical Publishing House, 1995: 638. |
| [7] | Maresca A, Zaffagnini M, Caporali L, et al. DNA methyltransferase 1 mutations and mitochondrial pathology: is mtDNA methylated? Front Genet 2015; 6: 90. |
| [8] | Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 116: 434-48. |
| [9] | Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85: 1093-1129. |
| [10] | Sara B, Daniele LB, Giuseppe T, et al. The role of nNOS and PGC-1α in skeletal muscle cells. J Cell Sci 2014; 127: 4813-20. |
| [11] | Tina W. Mitochondria and PGC-1α in aging and age-associated diseases. J Appl Packag Res 2011: 810619. |
| [12] | Xavier P, Laia S, Emma B, et al. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol 2013; 168: 3160-72. |
| [13] | Uguccioni G, Hood DA. The importance of PGC-1α in contractile activity-induced mitochondrial adaptations. Am J Physiol Endocrinol Metab 2011; 300: E361-71. |
| [14] | Joanne S. Ingwall. Energy metabolism in heart failure and remodeling. Cardiovasc Res 2009; 81: 412-9. |
| [15] | Jäger S, Handschin C, St-Pierre J, et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc Natl Acad Sci U S A 2007; |
| [15] | 104:12017-22. |
| [16] | Liu L, Huang X, Gao JL, et al. Improved endogenous epoxyeicosatrienoic acid production mends heart function via increased PGC 1a-mitochondrial functions in metabolic syndrome. J Pharmacol Sci 2018; 138: 138-45. |
| [17] | Yu LM, Gong B, Duan WX, et al. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-α-SIRT3 signaling. Sci Rep 2017; 7: 41337. |
| [18] | Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 2004; 94: 525-33. |
| [19] | Pere P, Zhidan W, Cheol WP, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-39. |
| [20] | Ventura CR, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1α. Cardiovasc Res 2008; 79: 208-17. |
| [21] | Jens FH, Henrik J, Jacob NM, et al. PGC-1α regulates mitochondrial properties beyond biogenesis with aging and exercise training. Am J Physiol 2019; 317: E513-25. |
| [22] | Larsson NG, Wang J, Wilhelmsson H, et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 1998; 18: 231-6. |
| [23] | Dongchon K, Sang HK, Naotaka H. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion 2007; 7: 39-44. |
| [24] | McLeod CJ, Jeyabalan AP, Minners JO, et al. Delayed ischemic preconditioning activates nuclear- encoded electron- transfer- chain gene expression in parallel with enhanced postanoxic mitochondrial respiratory recovery. Circulation 2004; 110: 534-9. |
| [25] | Anna H, Nicole H, Eric D, et al. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci 2004; 101: 3136-41. |
| [26] | Mathur A, Hong Y, Kemp BK, et al. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res 2000; 46: 126-38. |
| [27] | Zorova LD, Popkov VA, Plotnikov EJ, et al. Functional significance of the mitochondrial membrane potential. Biochemistry (Moscow), Biochem (Moscow) Suppl Ser 2018, 12: 20-6. |
| [28] | Liu XN, Rishi RC, Ichiro N, et al. The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 2014; 13: 596-605. |
| [29] | Martineau LC. Large enhancement of skeletal muscle cell glucose uptake and suppress ion of hepatocyte glucose-6-phos phatase activity by weak uncouplers of oxidative phosphorylation. Biochim Biophys Acta 2012; 1820: 133-50. |
| [30] | Wei YH, Wu S, Cao M, et al. Effects of SGS on hemodynamics, RhoA and ROCK1 in rats with pressure overload heart failure. Zhong Xi Yi Jie He Xin Xue Guan Bing Za Zhi 2014; 12: 65-7. |
| [31] | Liang YQ, Zhou L, Zhou D, et al. Effect of SGS on ventricular remodeling in rats with pressure overload. Zhong Cheng Yao 2014; 37: 1230-42. |
| [32] | Zhu LY, Wei YH, Zhou D, et al. Protective effect of SGS on mitochondrial function in rats with heart failure. Zhong Yi Za Zhi 2017; 58: 678-81. |
/
| 〈 |
|
〉 |